

Information For the User  
Glimepiride I.P. 3mg + Metformin Hydrochloride (S.R.) I.P. 500mg Bi-Layered Tablets

# Gimtype M3 Tablet

**Brand Name:** Gimtype M3 Tablet

**Dosage Form:** Bi-Layered Sustained-Release Tablet

**Composition:**

Each bi-layered tablet contains:

- Glimepiride IP 3 mg
- Metformin Hydrochloride IP 500 mg (Sustained Release)

**Description:**

Gimtype M3 Tablet is a combination of Glimepiride, a sulfonylurea antidiabetic agent, and Metformin Hydrochloride, a biguanide. This bi-layered sustained-release formulation is indicated for the management of type 2 diabetes mellitus when diet and exercise alone are insufficient. It helps in improving glycemic control by enhancing insulin secretion and reducing hepatic glucose production.

**Indications:**

Indicated for the treatment of:

- Type 2 diabetes mellitus
- Patients inadequately controlled on monotherapy

It helps in controlling fasting and post-prandial blood glucose levels.

**Dosage & Administration:**

Dosage should be as directed by the physician.

The tablet should be swallowed whole without crushing or chewing.

To be taken with meals to reduce gastrointestinal intolerance.

**Pharmacological Action:**

Glimepiride stimulates insulin release from pancreatic beta cells, while Metformin decreases hepatic gluconeogenesis, improves insulin sensitivity, and reduces intestinal glucose absorption. The sustained-release layer ensures prolonged glycemic control.

**Side Effects:**

Generally well tolerated.

Possible side effects include hypoglycemia, gastrointestinal disturbances such as nausea, diarrhea, abdominal discomfort, and headache.

**Precautions & Warnings:**

- Use with caution in patients with renal or hepatic impairment
- Monitor blood glucose levels regularly
- Risk of hypoglycemia, especially in elderly or debilitated patients
- Contraindicated in type 1 diabetes mellitus and diabetic ketoacidosis

**Drug Interactions:**

Concomitant use with other antidiabetic agents may increase the risk of hypoglycemia.  
Alcohol intake may potentiate the hypoglycemic effect and increase the risk of lactic acidosis.

**Storage:**

Store below 25°C in a cool, dry place.  
Protect from light and moisture.  
Keep out of reach of children.

Manufactured in India for:



**Cafoli Lifecare Pvt. Ltd.**

**(An ISO 9001: 2015 Certified Co.)**

Plot no.: 367-FF, Industrial Area Phase-I,  
Panchkula-134113

TM: Trademark Applied for